Repligen Corp. diskutieren
Repligen Corp.
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Aktie / Pharmazeutika / Mid Cap /
126,25 €
2,10 %
Repligen (RGEN) had its price target lowered by Wells Fargo & Company from $190.00 to $180.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target lowered by Barclays PLC from $200.00 to $175.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target lowered by UBS Group AG from $200.00 to $195.00. They now have a "buy" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target raised by HC Wainwright from $180.00 to $208.00. They now have a "buy" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) is now covered by Roth Mkm. They set a "buy" rating and a $160.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target lowered by JPMorgan Chase & Co. from $180.00 to $165.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its "outperform" rating reaffirmed by Wolfe Research. They now have a $145.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target lowered by HSBC Holdings plc from $170.00 to $150.00. They now have a "buy" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its "outperform" rating reaffirmed by Evercore Inc.
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) was upgraded by Citigroup Inc. to "buy".
Ratings data for RGEN provided by MarketBeat
Neueste Beiträge
Argus in Expedia Inc. diskutieren